AstraZeneca
AZN
$70.54
Share price
-0.14%
Change (1 day)
-11.13%
Change (1 year)
Categories
AstraZeneca (AZN) - Cash on Hand
Cash on Hand as of March 2025 : $5.39 Billion USD
According to AstraZeneca's latest financial reports the company has $5.39 Billion USD in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
AstraZeneca - Cash on Hand chart (from 1996 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | $5.65 B | -3.52% |
| 2023-12-31 | $5.86 B | -6.13% |
| 2022-12-31 | $6.24 B | -2.42% |
| 2021-12-31 | $6.39 B | -19.94% |
| 2020-12-31 | $7.99 B | 28.55% |
| 2019-12-31 | $6.21 B | 11.14% |
| 2018-12-31 | $5.59 B | 22.84% |
| 2017-12-31 | $4.55 B | -21.63% |
| 2016-12-31 | $5.81 B | -13.82% |
| 2015-12-31 | $6.74 B | -4.23% |
| 2014-12-31 | $7.04 B | -28.84% |
| 2013-12-31 | $9.89 B | 20.32% |
| 2012-12-31 | $8.22 B | -27.08% |
| 2011-12-31 | $11.27 B | -4.64% |
| 2010-12-31 | $11.82 B | 3.71% |
| 2009-12-31 | $11.40 B | 159.67% |
| 2008-12-31 | $4.39 B | -26.3% |
| 2007-12-31 | $5.95 B | -22.46% |
| 2006-12-31 | $7.68 B | 54.33% |
| 2005-12-31 | $4.97 B | -5.43% |
| 2004-12-31 | $5.26 B | 33.26% |
| 2003-12-31 | $3.95 B | -15.72% |
| 2002-12-31 | $4.68 B | 22.63% |
| 2001-12-31 | $3.82 B | -14.14% |
| 2000-12-31 | $4.45 B | 35.41% |
| 1999-12-31 | $3.28 B | -3.63% |
| 1998-12-31 | $3.41 B | 183.13% |
| 1997-12-31 | $1.20 B | -27.82% |
| 1996-12-31 | $1.66 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Bristol-Myers Squibb BMY | $11.78 B | 118.39% | 🇺🇸 USA |
 Pfizer PFE | $17.31 B | 220.96% | 🇺🇸 USA |
 Merck MRK | $9.22 B | 71.05% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $5.79 B | 7.41% | 🇬🇧 UK |
 Sanofi SNY | $8.64 B | 60.25% | 🇫🇷 France |
 Eli Lilly LLY | $3.22 B | -40.30% | 🇺🇸 USA |
 Johnson & Johnson JNJ | $38.78 B | 618.83% | 🇺🇸 USA |
 Abbott Laboratories ABT | $6.84 B | 26.86% | 🇺🇸 USA |
 Biogen BIIB | $2.59 B | -51.84% | 🇺🇸 USA |
 Novartis NVS | $7.19 B | 33.38% | 🇨🇭 Switzerland |